Contents
On this page
- The NIH impact score scale and funding paylines
- Establishing significance without reliance on disease burden
- Positioning the research question within the hallmarks of cancer framework
- Demonstrating novelty in a crowded therapeutic landscape
- Finalising the protocol before costing the study
- Anticipating criticism of the execution plan
- Feasibility arguments for tissue, cohorts and models
- Considerations for early-stage investigators
- Recommended order of drafting
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · cancer research proposal
Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility
Cancer research proposals are assessed on a scale on which small differences are decisive: National Institutes of Health (NIH) impact scores of 10 to 30, approximately the top 15th percentile, are the most likely to be funded, and scores above 45 are rarely funded. In oncology, points are most consistently lost through a significance argument based on disease burden rather than on a mechanism, and through an execution plan that describes intent rather than procedure. This article examines both.
Cancer research proposals conventionally open with the burden of the disease, although this is seldom necessary. Reviewers on an oncology panel already accept the importance of cancer; their assessment concerns whether the question is positioned where a result would change something, and whether the plan is capable of producing that result. The scoring is exacting: comments on the plan for execution appeared in 82.7 per cent of unfunded applications compared with 61.8 per cent of funded ones, and each one-point worsening of score reduced the odds of funding sharply. A proposal is therefore unlikely to succeed on the strength of its burden paragraph.
Learning objectives
- The operation of impact scores and paylines, and the score band for which a proposal is effectively written
- The use of disease burden in a significance argument without attracting the standard objection
- Positioning a research question against the hallmarks framework so that its scope is clearly defined
- The implications of more than 90 approved targeted agents for a novelty claim, and how they may be addressed
- The protocol items that must be fixed before a proposal can be costed
- Writing an execution plan that withstands the criticism it is very likely to attract
Common misconceptions
- “Opening with the cancer burden establishes significance.” The projected rise of approximately 50 per cent in global cancer burden over the next twenty years applies equally to every cancer proposal submitted. A figure that does not discriminate between one proposal and another cannot establish the significance of either.
- “A good score means funding.” Funding depends on the payline. One institute’s payline stood at 16 per cent, or 25 per cent for early stage investigators; the same score may therefore be funded at one institute and not at another, and for one applicant but not for a colleague.
- “Reviewers criticise the plan when the plan is bad.” Comments on the plan for execution also appeared in 61.8 per cent of funded applications. Criticism of execution is close to universal; the relevant question is whether the plan withstands it.
- “Targeted therapy is still a wide-open field.” More than 90 small-molecule targeted drugs are already approved for clinical use. A novelty claim that does not engage with that landscape is likely to be read as unfamiliarity with it.
- “We will write the protocol after the grant is awarded.” A trial or intervention proposal must specify the minimum protocol items (34 in SPIRIT 2025) before it can be costed accurately. Costing a study whose outcome definitions and analysis plan are undecided produces a budget that is unlikely to remain valid once the work begins.
The NIH impact score scale and funding paylines
The proposal should be written with the scoring mechanism in mind, because it determines the available margin. National Institutes of Health (NIH) impact scores of 10 to 30 — roughly the top 15th percentile — are the applications most likely to be funded, and scores above 45 are rarely funded 19. The entire competitive population falls between those two statements. One institute’s payline was 16 per cent, rising to 25 per cent for early stage investigators, which indicates that the same score has different consequences depending on the institute and the applicant’s career stage.
The sensitivity of the outcome to small score movements is the operative fact. In a dataset from a disease-specific research foundation, each one-point worsening of review score reduced the odds of funding sharply, with an odds ratio of 0.058 per point, and the mean score was 3.25 among funded applications against 5.98 among unfunded ones 25. The margin between funded and unfunded applications is narrow, and most of the recoverable points lie outside the science: in whether the reviewer can locate the research question, whether the plan is costed at the level of individual pieces of work, and whether the risks are identified by the applicant rather than discovered by the reviewer 25,26.
Two practical consequences follow. First, applicants should check the payline for the relevant institute or scheme before writing, because it indicates whether the proposal is competing for the top sixth of applications or the top quarter. Second, applicants eligible for an early-stage designation should confirm it formally, since the difference between a 16 per cent and a 25 per cent payline substantially changes the prospect of funding at the same score. The Pubrica page on what makes grant writing hard sets out the wider base rates.
Score bands, paylines and their implications for the draft
| Figure | Value | What it tells you |
|---|---|---|
| NIH impact score most likely to be funded | 10 to 30, roughly the top 15th percentile | The proposal competes for the top sixth of the applicant pool, not against an acceptable standard |
| Impact score rarely funded | Above 45 | A proposal with one weak aim can fall into this band without the science being flawed |
| Institute payline, general | 16 per cent | Whether the same score is funded depends on the institute to which the application is made |
| Institute payline, early stage investigator | 25 per cent | Eligibility should be confirmed formally; it is the single largest lever available to a new applicant |
| Mean review score, funded applications | 3.25 | At one disease-specific foundation, on a scale where lower is better |
| Mean review score, unfunded applications | 5.98 | The decision margin is roughly two and a half points of mean score |
| Odds of funding per one-point worsening | Odds ratio 0.058 | A single point has a very large effect on the odds of funding, which is why structural faults matter |
NIH impact score bands and the percentile they correspond to; one institute’s general and early-stage-investigator paylines; and review score data from 240 applications to a disease-specific research foundation, of which 55 were funded. Paylines change annually and by institute; the current figure for the relevant scheme should be checked rather than any published number relied upon.
Establishing significance without reliance on disease burden
The global cancer burden is projected to rise by roughly 50 per cent over the next twenty years 9. This is a genuine and important projection, but it is seldom appropriate where applicants place it. It cannot establish the significance of a proposal because it is equally true of every competing proposal, and a reviewer who encounters it on the first page learns only that the applicant has used the most readily available statistic.
Burden data should be used where they discriminate. They are legitimate and useful when the specific burden is unexpected — a subtype whose incidence is rising against the trend, a population in which outcomes have not improved while others have, a setting where a standard intervention is unavailable. In those cases the figure serves a purpose: it identifies a group for whom the answer to the research question would matter more than average. Burden data are also acceptable as a single clause of orientation, but not as a paragraph.
What establishes significance instead is a chain: a mechanism or clinical problem, a decision that currently cannot be made well, and a result from the proposed work that would change that decision 31,36. The chain should be written explicitly, with the position of the award within it identified. The most common oncology overclaim is to end the chain at patient benefit when the proposal is three steps removed from it, and a panel that treats translational claims sceptically will notice. The Pubrica page on writing the rationale covers how to argue significance without borrowing from a future you are not funded to reach.
The significance paragraph of a cancer research proposal
Burden statistics standing in for an argument
Cancer remains one of the leading causes of death worldwide, and the global cancer burden is projected to rise by approximately 50 per cent over the next two decades. Despite the approval of more than 90 small-molecule targeted therapies, outcomes for many patients remain poor and there is an urgent unmet need for novel therapeutic strategies. The proposed research will investigate novel mechanisms of resistance, with the potential to improve survival for patients with advanced disease.
The burden projection does not discriminate. A roughly 50 per cent rise in global cancer burden over twenty years is equally true of every proposal on the panel, so it cannot establish the significance of this one.
“Despite more than 90 approved targeted therapies” is used as a complaint rather than as context. It invites the obvious question of what remains to be done, without answering it.
“Urgent unmet need” and “novel therapeutic strategies” name no need and no strategy. Both phrases persist in drafts precisely because they cannot be verified.
“Novel mechanisms of resistance” is an activity, not a result. There is no decision anywhere in the paragraph that a finding would change.
“Potential to improve survival” ends the chain at patient benefit while the proposal sits several steps short of it, which is the overclaim an oncology panel is attuned to detect.
A chain from problem to decision to result
Patients with this subtype respond to first-line inhibition at a high initial rate, and almost all relapse within [n] months. At relapse the clinician faces a decision with no evidence base: whether to escalate within the same target class or switch mechanism. The choice currently rests on institutional habit, because the two resistance routes reported in this setting — secondary target mutation and bypass pathway activation — cannot be distinguished with any assay available at the point of care, and the published series that describe them did not sample at relapse. Our work would produce the discriminating measurement: if intratumoural bypass activation is detectable in relapse biopsies and predicts non-response to within-class escalation, as our preliminary series of [n] cases suggests, then a single assay at relapse would reassign a substantial share of these patients away from an ineffective second line. This award delivers the assay and the retrospective validation; the prospective trial that would change guidelines is the subsequent step and is not proposed here.
The burden is specific to a subtype and a time window, so the number identifies a group for whom the answer matters more than average.
A clinical decision is named, which converts significance from an assertion into a consequence.
The reason the decision cannot currently be made well is methodological and stated, so the gap is explained rather than claimed.
The deliverable of this award is distinguished from the trial that would change practice, which removes the overclaim while keeping the ambition visible.
Preliminary data is attached to the central claim, so the feasibility argument and the significance argument reinforce each other.
With funded applications averaging 3.25 against 5.98 for unfunded ones, and each point of score worth an odds ratio of 0.058, a significance section that could have been written about any cancer proposal is likely to cost a point before the plan is even read.
Positioning the research question within the hallmarks of cancer framework
The hallmarks framework sets out six core hallmarks of cancer, two enabling characteristics and two emerging hallmarks. Its value in a proposal lies not in citation of record but in positioning: it allows the applicant to state, in one sentence, which part of cancer biology the question occupies and which parts it does not.
Applicants frequently omit the second element, which reviewers value. A proposal that states that it addresses proliferative signalling, and explicitly does not address the immune or metabolic dimensions, has defined its scope and appears decisive. A proposal that refers loosely to the whole framework appears not to have made a choice. The scoping sentence also pre-empts a predictable objection, because a reviewer whose specialism lies in an unaddressed hallmark will be reassured that the applicant is aware of it and has deliberately bounded the work.
Two cautions apply. The framework is a conceptual organisation of cancer biology, not a mechanistic prediction, so it should not be used in place of a hypothesis; naming a hallmark is not the same as stating a mechanism that predicts an observation 33. Where the question is clinical or health-services in nature rather than biological, the framework is inappropriate, and the care pathway or the decision point should be used instead. For dissertation-scale positioning, the Pubrica page on oncology dissertation topics in the molecular and cellular basis of cancer works through the framework in more detail.
The hallmarks framework as a positioning device: six core hallmarks, two enabling characteristics and two emerging hallmarks. It can be used to state which part of cancer biology a question occupies and, more usefully, which parts it does not.
Demonstrating novelty in a crowded therapeutic landscape
More than 90 small-molecule targeted drugs are approved for clinical use 9. For applicants proposing work on targeted therapy, that figure sets the threshold for a novelty claim and also provides the response to the obvious objection.
The objection is that the target class has been extensively investigated and that little remains to be done. Three responses are usually available, and all require specificity. Resistance — approved agents generate resistance, and the mechanism of resistance to a specific agent in a specific setting is frequently unresolved. Patient selection — an approved agent works in a subset, and which subset, and why, is often an open question with direct clinical consequence 23. Combination and sequence — a landscape of ninety agents generates a combinatorial space that cannot be explored empirically in trials, which makes a principled basis for selecting combinations genuinely valuable.
A novelty claim resting on a target not previously drugged, with no account of why it has not been, is unconvincing. Reviewers in this field know the history of most attractive-looking targets, and the usual explanation is that an attempt has already been made. Where a proposed target has a failed history, the proposal should state this and explain what is different — a new chemotype, a new context, a better biomarker. Declaring the failed history is a strength; omitting it suggests unfamiliarity. The Pubrica cancer research subject support and oncology and haematology therapeutic pages cover the landscape work this argument needs.
Finalising the protocol before costing the study
If the proposal includes a trial or an intervention, the minimum protocol items (34 in SPIRIT 2025) should be specified before the budget is built 28. This is not a formality. Several of those items determine the cost: the primary outcome and how it is measured, the eligibility criteria that set the recruitment rate, the assessment schedule that drives visit costs, the analysis plan that sets the sample size, the monitoring arrangement, the data-management infrastructure 2,28.
Costing a study whose outcome definitions are undecided produces a budget that is inaccurate in both directions. It is usually too low for data management and monitoring, which remain invisible until specified, and it frequently assumes a recruitment rate that the eligibility criteria make impossible. Both errors emerge in review, and the second is fatal to the application, because a reviewer who recalculates recruitment from the stated criteria and site count and obtains a different answer has found a reason to doubt everything else.
The recommended order is outcomes, then eligibility, then schedule, then analysis plan and sample size, then budget. Where a full protocol cannot be written in time, the items that drive cost should be written and the remainder referenced as to be completed, with the governance route named. The SPIRIT checklist lists the items; protocol development and statistical analysis plan support are where the cost-driving decisions are made. For preclinical proposals, the analogous discipline is to fix the endpoint, the effect size for which the study is powered and the analysis before costing the animal or cell work — see trial and study design options.
Anticipating criticism of the execution plan
Comments on the plan for execution appeared in 61.8 per cent of funded applications and 82.7 per cent of unfunded ones, a difference unlikely to be chance 25. These two figures indicate that execution criticism is the normal condition of a reviewed proposal, including a successful one 25. The objective is therefore not a plan that attracts no criticism but one that withstands it.
Plans that withstand criticism share four features. The work is decomposed into units small enough to be costed and scheduled, each with an owner, a duration and a deliverable. Each unit has a stated consequence of failure: the alternative course of action if the unit does not succeed, and its cost. The timeline reconciles arithmetically with the budget and with the aims, using the same labels throughout 2,26. Finally, the dependencies are declared, so that a reviewer can see which pieces of work are on the critical path and whether the plan has any slack.
Plans that do not survive describe intent. “We will characterise”, “samples will be analysed”, “the cohort will be recruited” — these are statements of what is supposed to happen with no account of how, by whom, or in what order. The gap between the two kinds of plan is almost entirely a matter of specificity rather than of effort, which makes it the cheapest available improvement to a proposal.
Execution criticism is near-universal, including among funded applications. Frequency of reviewer comments on the plan for execution among 240 applications to a disease-specific research foundation, of which 55 were funded.
Feasibility arguments for tissue, cohorts and models
Oncology proposals fail on resource feasibility more often than on scientific merit, and the pattern is consistent enough to anticipate. Four claims are routinely checked.
Sample availability. If the work requires human tumour tissue, a reviewer expects the source, the governance route, the realistic accrual rate and evidence that material of the required quality exists 10. “Samples will be obtained from our biobank” is not a feasibility argument unless the biobank’s holdings for the specific requirement are stated.
Recruitment arithmetic. Eligibility criteria, site count, and the annual eligible population in those sites must yield the powered sample size within the award period, allowing for attrition 28. Reviewers perform this calculation; applicants should perform it first, present it, and state the contingency if accrual falls below projection.
Model-system appropriateness. The model must be capable of demonstrating the effect under investigation. Where a model has a known limitation — a cell line without the relevant pathway intact, a xenograft without an immune compartment — the proposal should name the limitation and state its consequences for the inference.
Assay validity. The readout must be validated at the scale and in the matrix in which it will be used. This is the feasibility claim applicants most often assert and least often evidence, and its absence undermines every number the project would produce. The Pubrica page on developing and evaluating an instrument covers the equivalent problem for patient-reported measures, and biostatistics support is where the sizing gets checked.
Considerations for early-stage investigators
The payline difference is important because it changes what the applicant should optimise. One institute’s payline was 16 per cent generally and 25 per cent for early stage investigators 19. That is a materially different competition, and it rewards a different emphasis: at the more favourable payline, a focused, clearly executable proposal with modest scope is likely to outscore an ambitious one with execution doubts, because the required score band is attainable without an exaggerated significance claim.
Three concrete implications follow. Eligibility status should be confirmed formally and early, because designations have definitions and are not automatic. Scope should be chosen for defensibility rather than impressiveness: a two-aim proposal with no execution doubt is a stronger prospect than a three-aim proposal with one weak aim, given the cost of a single point of score. Applicants should also invest disproportionately in the feasibility and environment material, because the standard objection to an early-career applicant does not concern the idea 10,36.
Where the applicant lacks a track record in a specific method, a collaborator who has one should be recruited and the arrangement made concrete: named person, named contribution, letter attached 14. An unevidenced collaboration is worse than none, because it draws attention to the gap it was meant to cover.
Recommended order of drafting
The sequence of drafting matters more than the prose. The primary question should be written first, as one sentence, and drafting should not proceed until it remains clear when read aloud to someone outside the project 1. The aims follow, framed as outcomes rather than activities, with their independence from each other tested explicitly 18,30. Next come the cost-driving protocol or design decisions: outcomes, eligibility, schedule, analysis plan, sample size. The budget follows, then the execution plan and timeline, reconciled against the budget, and then the feasibility and resource arguments, with their evidence attached. Significance comes next, as it is considerably easier to write once the deliverables of the work are known precisely. The burden sentence comes last, and only if it still serves a purpose.
Writing in this order has one specific benefit: the significance section describes the actual deliverable rather than the aspiration, which is what removes the overclaim. It also means that the budget is built on decisions rather than estimates, so the recruitment and cost arithmetic that reviewers check is more likely to reconcile.
Three weeks should be allowed for an internal structural review by someone outside the project, and that review should be treated as the point at which the plan can still change. Given the value of a single point of score, a reader who identifies one unnamed risk justifies the time invested. Proposal development and grant writing support are the Pubrica services that conduct this review, and the Pubrica guide to medical grant proposal writing covers the submission cycle around it.
Key points
Key points
Cancer proposals are decided within a narrow score band — impact scores of 10 to 30, approximately the top 15th percentile, are most likely to be funded and scores above 45 rarely are — against paylines that differ by institute and career stage, such as 16 per cent generally and 25 per cent for early stage investigators. The opening should not rely on the projected 50 per cent rise in global cancer burden, because it applies equally to every competing proposal; significance should instead be constructed as a chain from a mechanism or clinical decision to a result that the award would produce. The research question should be positioned against the hallmarks framework, stating which of the six core hallmarks, two enabling characteristics and two emerging hallmarks are not addressed. The more than 90 approved targeted agents should be engaged with rather than ignored, usually through resistance, patient selection or combination. The 33 protocol items that drive cost should be fixed before the budget is constructed. The execution plan should be written to withstand criticism, because execution comments appeared in 61.8 per cent of funded applications as well as 82.7 per cent of unfunded ones.
Application to your study
Application to your study
- Applicants should consult the current payline before drafting. The relevant payline is specific to the institute and scheme, and differs for general and early-stage applicants. It indicates whether the proposal is competing for the top sixth or the top quarter of applications.
- The opening burden paragraph should be replaced by a significance argument constructed as a chain. The chain links the mechanism or clinical problem, the decision that currently cannot be made well, and the result from the award that would change it.
- A single sentence should define the scope of the question within the hallmarks framework. This sentence names the area of cancer biology that the question occupies and the areas it deliberately excludes. A clearly bounded question is rewarded in scoring; breadth is not.
- The crowded-landscape objection should be addressed explicitly. With more than 90 approved targeted agents, a novelty claim should rest on resistance, patient selection or combination, and any failed history of the target should be declared.
- Outcomes, eligibility, schedule, analysis plan and sample size should be fixed before any costing is undertaken. The recruitment arithmetic that a reviewer will perform should then be carried out and presented.
- Each unit of work should have an owner, a duration, a deliverable and a stated consequence of failure. A plan without stated failure consequences is a statement of intent.
- Every resource claim should be supported by evidence. This includes the sample source and accrual rate, named model limitations, and validation of the assay in the relevant matrix and at the intended scale.
- An internal structural review should be scheduled three weeks before the deadline. A single unidentified risk detected by an external reader is of greater value than a further week of polishing.
Frequently asked questions
Scores of 10 to 30 — roughly the top 15th percentile — are the ones most likely to be funded, and scores above 45 are rarely funded. However, the score alone does not determine the outcome: funding depends on the payline, which varies by institute, by year and by applicant category. One institute’s payline stood at 16 per cent generally and 25 per cent for early stage investigators, so the same score can be funded for one applicant and not for another. Applicants should consult the current figure for the specific institute and scheme before drafting, because it indicates the score band to be reached and therefore how much execution risk the proposal can carry.
Almost never in the way applicants typically use it. The projected rise of roughly 50 per cent in global cancer burden over the next twenty years is true of every proposal on the panel, so it cannot distinguish any one of them, and a reviewer who encounters it on the first page learns only that the applicant used the most readily available number. Burden data are justified when they discriminate: a subtype whose incidence is rising against the trend, a population whose outcomes have not improved while others have, a setting where a standard intervention is unavailable. In such cases they identify a group for whom the answer matters more than average. Otherwise, burden data should occupy at most a clause of orientation, with the paragraph devoted to the decision the result would change.
As a positioning device rather than a citation of record. The framework sets out six core hallmarks, two enabling characteristics and two emerging hallmarks, and one sentence naming which of them the question occupies, and which it deliberately does not, makes the scope clear to a panel whose members specialise across the whole framework. Applicants often omit the exclusion, which reviewers value because it signals a decision rather than ambition. Two cautions apply: the framework organises cancer biology conceptually and does not supply a mechanism, so naming a hallmark is not stating a hypothesis; and for clinical or health-services questions it is inappropriate, and the care pathway or decision point is more suitable.
Through one of three routes, each requiring specificity. Resistance: approved agents generate resistance, and the mechanism in a given agent and setting is frequently unresolved. Patient selection: an agent works in a subset, and identifying which subset and why has direct clinical consequence. Combination and sequence: ninety-plus agents generate a combinatorial space too large to explore empirically in trials, so a principled basis for choosing combinations is genuinely valuable. A claim resting on a target that has never been drugged, with no account of why, is unconvincing; reviewers in this field usually know that an attempt has been made. If the target has a failed history, the proposal should state this and explain what is now different. Declaring it is a strength; omitting it suggests unfamiliarity.
The parts of the protocol that determine cost are required, and these amount to more than most applicants write. The protocol standard, SPIRIT 2025, specifies 34 items, and several of them set the budget directly: the primary outcome and its measurement, the eligibility criteria that set the recruitment rate, the assessment schedule that drives visit costs, the analysis plan that fixes the sample size, the monitoring and data-management arrangements. Costing before those are decided produces a budget that is usually too low on data management and too optimistic on accrual, and the accrual error is the more serious, because a reviewer who recalculates recruitment from the applicant’s own criteria and site count and obtains a different number has a reason to doubt everything else.
Almost certainly. Comments on the plan for execution appeared in 61.8 per cent of funded applications and 82.7 per cent of unfunded ones, a difference unlikely to be chance but far from a clean separation. The objective is therefore resilience to criticism rather than immunity from it. Plans that withstand criticism decompose the work into units with an owner, a duration, a deliverable and a stated consequence of failure; reconcile the timeline arithmetically with the budget and the aims using consistent labels; and declare dependencies so that the critical path is visible. Plans that do not withstand it describe intent — samples will be analysed, the cohort will be recruited — with no account of how, by whom or in what order. The difference lies in specificity, not effort.
Four claims are reliably checked. Sample availability: the source, the governance route, the realistic accrual rate, and evidence that material of the required quality exists; naming a biobank is not an argument unless its holdings for the specific requirement are stated. Recruitment arithmetic: eligibility criteria times site count times eligible annual population, with attrition, must produce the powered sample size within the award period. Model appropriateness: whether the model can show the effect at all, with known limitations named rather than left to be discovered. Assay validity in the matrix and at the scale of intended use: this is the claim most often asserted and least often evidenced, and its absence undermines every number the project would produce.
Early-stage applicants should prioritise executability over ambition, because the more favourable payline rewards that choice. With a payline of 25 per cent for early stage investigators against 16 per cent generally, a two-aim proposal with no execution doubt is a stronger prospect than a three-aim proposal with one weak aim — particularly given that each point of score worsening carried an odds ratio of 0.058 in one dataset. Three practical steps follow: the eligibility designation should be confirmed formally and early, since it is not automatic; feasibility, environment and resource evidence warrant disproportionate investment, because that is where the standard objection to a new applicant is directed; and where the applicant lacks a track record in a method, a named collaborator with a concrete contribution and a letter should be attached, since a vague collaboration draws attention to the gap it was intended to cover.
References
- Willis LD. Formulating the Research Question and Framing the Hypothesis. Respiratory Care. 2024;69(4). doi:10.4187/respcare.10975 read 9 October 2026. doi.org/10.4187/respcare.10975
- Patil SG. Budgeting the Project: Detailing the Required Funding and Expenditure. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:77-91. doi:10.1007/978-981-19-7018-4_7 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_7
- Rajappa M. Checklist for Grant Proposal: Mandatory Elements. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:161-165. doi:10.1007/978-981-19-7018-4_14 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_14
- Joshi M, Joshi P, Smith JA. Dealing with the Rejected Grant Proposal: Learning from the Mistakes. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:179-187. doi:10.1007/978-981-19-7018-4_16 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_16
- Rahi M, Sharma S, Yadav B. Funders' Perspective: What the Funding Body Expects from Researchers? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:21-31. doi:10.1007/978-981-19-7018-4_3 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_3
- Dubashi B, Ramadass B. Funding Organizations for Science and Health Care. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:33-52. doi:10.1007/978-981-19-7018-4_4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_4
- Parija SC, Kate V (eds). Grant writing for medical and healthcare professionals. Springer, Singapore. 2023. doi:10.1007/978-981-19-7018-4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4
- Weidmann AE, Cadogan CA, Fialova D, et al. How to write a successful grant application: guidance provided by the European Society of Clinical Pharmacy. International Journal of Clinical Pharmacy. 2023;45(3):781-786. doi:10.1007/s11096-023-01543-7 read 9 October 2026. doi.org/10.1007/s11096-023-01543-7
- Han C, Zhan Q. Precision medicine revolutionizes cancer diagnosis and treatment. Medical Review. 2023;2(6):541-543. doi:10.1515/mr-2022-0041 read 9 October 2026. doi.org/10.1515/mr-2022-0041
- Singaravelu SLD. Proving the Competency of the Researcher and the Adequacy of the Infrastructure to Carry Out the Research. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:93-101. doi:10.1007/978-981-19-7018-4_8 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_8
- Nachiappa Ganesh R. Tips for Improvising the Chance of Getting the Grant. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:167-177. doi:10.1007/978-981-19-7018-4_15 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_15
- Parija SC, Shrivastava SR. What Is Your Aim (Ambition-Interest-Mission), and What You Want to Do? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:3-12. doi:10.1007/978-981-19-7018-4_1 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_1
- What Is a Grant? How to Prepare a Grant Proposal Application. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:13-20. doi:10.1007/978-981-19-7018-4_2 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_2
- Barreto SG. Writing a Grant Proposal for a Collaborative Study. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:153-159. doi:10.1007/978-981-19-7018-4_13 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_13
- Kate V, Gupta D, Balakrishnan G. Writing a Grant Proposal for a Single Centre Study: Step-by-Step Approach. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:63-76. doi:10.1007/978-981-19-7018-4_6 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_6
- Ganguly NK, Saha GK. Writing an Impressive Cover Page (Covering Letter) and Abstract for Grant Proposal Application. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:117-131. doi:10.1007/978-981-19-7018-4_10 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_10
- Monavarian M. Basics of scientific and technical writing: Grant proposals. MRS Bulletin. 2021;46(5):455-457. doi:10.1557/s43577-021-00105-4 read 9 October 2026. doi.org/10.1557/s43577-021-00105-4
- Dhir SK, Gupta P. Formulation of Research Question and Composing Study Outcomes and Objectives. Indian Pediatrics. 2021;58:584-588. read 9 October 2026. indianpediatrics.net
- Kan P, Mokin M, Mack WJ, et al. Strategies for writing a successful National Institutes of Health grant proposal for the early-career neurointerventionalist. Journal of NeuroInterventional Surgery. 2020. doi:10.1136/neurintsurg-2020-016964 read 9 October 2026. doi.org/10.1136/neurintsurg-2020-016964
- Taylor RB. How to Write a Research Protocol. Medical Writing (Springer, Cham). 2018:239-260. doi:10.1007/978-3-319-70126-4_9 read 9 October 2026. doi.org/10.1007/978-3-319-70126-4_9
- Shepherd J, Frampton GK, Pickett K, et al. Peer review of health research funding proposals: A systematic map and systematic review of innovations for effectiveness and efficiency. PLoS ONE. 2018;13(5):e0196914. doi:10.1371/journal.pone.0196914 read 9 October 2026. doi.org/10.1371/journal.pone.0196914
- Boyack KW, Smith C, Klavans R. Toward predicting research proposal success. Scientometrics. 2018;114(2):449-461. doi:10.1007/s11192-017-2609-2 read 9 October 2026. doi.org/10.1007/s11192-017-2609-2
- Chae YK, Pan AP, Davis AA, et al. Path toward precision oncology: Review of targeted therapy studies and tools to aid in defining 'actionability' of a molecular lesion and patient management support. Molecular Cancer Therapeutics. 2017;16(12):2645-2655. doi:10.1158/1535-7163.MCT-17-0597 read 9 October 2026. doi.org/10.1158/1535-7163.MCT-17-0597
- Dey SK, Gerhardt K. How to Write a Competitive R01 Grant. Springer, Cham. 2016. doi:10.1007/978-3-319-41360-0 read 9 October 2026. doi.org/10.1007/978-3-319-41360-0
- Hume KM, Giladi AM, Chung KC. Factors Impacting Successfully Competing for Research Funding: An Analysis of Applications Submitted to The Plastic Surgery Foundation. Plastic and Reconstructive Surgery. 2015;135(2):429e-435e. doi:10.1097/PRS.0000000000000904 read 9 October 2026. doi.org/10.1097/PRS.0000000000000904
- Agency for Healthcare Research and Quality. Common Problems Identified During Peer Review. Agency for Healthcare Research and Quality (AHRQ). 2014. read 9 October 2026. ahrq.gov
- Herbert DL, Barnett AG, Clarke P, Graves N. On the time spent preparing grant proposals: an observational study of Australian researchers. BMJ Open. 2013;3(5):e002800. doi:10.1136/bmjopen-2013-002800 read 9 October 2026. doi.org/10.1136/bmjopen-2013-002800
- Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200-207. doi:10.7326/0003-4819-158-3-201302050-00583 read 9 October 2026. doi.org/10.7326/0003-4819-158-3-201302050-00583
- Abdoul H, Perrey C, Amiel P, et al. Peer Review of Grant Applications: Criteria Used and Qualitative Study of Reviewer Practices. PLoS ONE. 2012;7(9):e46054. doi:10.1371/journal.pone.0046054 read 9 October 2026. doi.org/10.1371/journal.pone.0046054
- National Institute of Allergy and Infectious Diseases (NIAID). Strategy for NIH Funding: Ten Steps to a Winning R01 Application. National Institutes of Health (NIAID). 2012. read 9 October 2026. ipr.osu.edu
- Proctor EK, Powell BJ, Baumann AA, et al. Writing implementation research grant proposals: ten key ingredients. Implementation Science. 2012;7(1):96. doi:10.1186/1748-5908-7-96 read 9 October 2026. doi.org/10.1186/1748-5908-7-96
- Hollins Martin CJ, Fleming V. A 15-step model for writing a research proposal. British Journal of Midwifery. 2011;18:791-798. read 9 October 2026. napier-repository.worktribe.com
- Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144. doi:10.1016/j.cell.2011.02.013 read 9 October 2026. doi.org/10.1016/j.cell.2011.02.013
- Eve J. Writing a research proposal: planning and communicating your research ideas effectively. Library and Information Research. 2009;32(102):18-28. doi:10.29173/lirg92 read 9 October 2026. doi.org/10.29173/lirg92
- SUNY Geneseo Sponsored Research (adapted from Locke, Spirduso and Silverman, Proposals That Work, 2nd ed., Sage, 1987). Common Reasons Grant Proposals Are Rejected. SUNY Geneseo Office of Sponsored Research. read 9 October 2026. geneseo.edu
- National Institute of Mental Health. Grant Writing Assistance. National Institutes of Health (NIMH). read 9 October 2026. nimh.nih.gov
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility. Pubrica. https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/
Pubrica Academy. “Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility.” Pubrica, 9 Oct. 2026, pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/.
Pubrica Academy (2026) Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility. Pubrica. Available at: https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/ (Accessed: 15 October 2026).
Pubrica Academy. “Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility.” Pubrica. October 9, 2026. https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/
Pubrica Academy, ‘Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/> accessed 15 October 2026.
Pubrica Academy. Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/
Pubrica Academy, “Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/
@misc{cancer_research_writing_how_to_plan_an_2026,
author = {{Pubrica Academy}},
title = {Planning and Writing a Cancer Research Proposal: Impact Scores, Significance and Feasibility},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/research/cancer-research-writing-how-to-plan-and-write-a-research-proposal/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Cancer proposal planning sequence, with the cost-driving decisions first
The steps should be followed in order. The sequence is deliberate: the protocol and design decisions precede the budget, and significance comes near the end, once the deliverables of the award are known precisely. Writing significance last is what removes the overclaim.
CANCER RESEARCH PROPOSAL PLANNING SEQUENCE
STEP 0. THE COMPETITION YOU ARE WRITING FOR
Scheme and institute: ______________________________
Current payline, general ........................... ______ %
Current payline, my applicant category ............. ______ %
Am I eligible for an early-stage designation? yes / no / checking
Formal confirmation obtained? yes / no Date: ______________
Score band I need to reach: ______________
(benchmark: impact scores 10 to 30, roughly the top 15th
percentile, are most likely funded; above 45 rarely funded)
STEP 1. THE QUESTION (one sentence; do not proceed until it survives)
Primary question: ____________________________________________
Read aloud to someone outside the project? yes / no
Could they restate it correctly afterwards? yes / no
One primary objective stated: ______________________
Secondary objectives (5 or fewer):
1. ______________ 2. ______________ 3. ______________
4. ______________ 5. ______________
STEP 2. POSITIONING
Hallmark(s) this question occupies: ______________________
Hallmarks this question DELIBERATELY does not address:
____________________________________________
(this sentence goes into the proposal; it signals a decision)
If this is a clinical or services question, the map is the care
pathway instead - decision point addressed: ______________
NOVELTY, against a landscape of more than 90 approved targeted agents:
[ ] Resistance - mechanism unresolved for: ______________
[ ] Patient selection - subset unidentified for: ______________
[ ] Combination or sequence - space unexplorable because: ______
[ ] Other: ______________________
Does my target have a FAILED history? yes / no
If yes, what is different now: ______________________
[ ] This is stated in the proposal, not omitted
STEP 3. AIMS (outcomes, not activities; 2 to 4 of them)
AIM 1. Determine whether ____________________________________
Comparator or baseline: ______________________
Endpoint and the validated assay for it: ______________________
Outcome if yes: ______________ Outcome if no: ______________
Independent of other aims? yes / no
AIM 2. (same fields)
AIM 3. (same fields)
[ ] No aim requires another aim to succeed first
(if one does, the contingency is stated in Risks)
STEP 4. COST-DRIVING DECISIONS (BEFORE any budget work)
For a trial or intervention, the items that set the cost:
Primary outcome and how measured: ______________________
Secondary outcomes: ______________________
Eligibility criteria, inclusion: ______________________
Eligibility criteria, exclusion: ______________________
Assessment schedule, visits per participant: ______
Analysis plan, principal comparison: ______________________
Sample size, and what it is powered for: ______________
Monitoring arrangement: ______________________
Data management platform: ______________________
Governance route and approval lead time: ______ weeks
[ ] All 33 protocol items reviewed; those not yet fixed are
listed as outstanding with the route to fixing them
For preclinical work, the equivalent:
Endpoint: ______________________
Effect size being powered for, and its source: ______________
Number of biological replicates, and the basis: ______________
Analysis decided in advance: ______________________
RECRUITMENT ARITHMETIC (do this before the reviewer does)
Eligible population per site per year ............. ______
Number of sites .................................. ______
Expected consent rate ............................ ______ %
Expected attrition ............................... ______ %
Recruits achievable within the award .............. ______
Sample size required .............................. ______
[ ] Achievable exceeds required
If not, contingency: ______________________
STEP 5. BUDGET (only now)
[ ] Every line traces to a decision made in Step 4
[ ] Data management and monitoring are costed, not assumed
[ ] Salary costs respect the applicable cap
[ ] In-kind and partner contributions are stated with values
STEP 6. EXECUTION PLAN (assume it will be criticised)
For EACH unit of work:
Label ______ Owner ______ Months ____ to ____
Deliverable: ______________________
If it fails: ______________________ Cost of that failure: ______
Depends on: ______________ On the critical path? yes / no
[ ] Same labels used in aims, plan, timeline and budget
[ ] Timeline reconciles arithmetically with the budget
[ ] Critical path identified; slack stated
[ ] No sentence in the plan is purely a statement of intent
STEP 7. FEASIBILITY AND RESOURCES (evidence, not assertion)
Sample source: ______________ Governance route: ______________
Holdings or accrual rate for MY requirement: ______________
Evidence attached: ______________________
Model system: ______________ Known limitation: ______________
What that limitation costs the inference: ______________
Assay: ______________ Validated in this matrix? yes / no
Reproducibility figure, and where it is reported: ______________
Named collaborators, with contribution and letter:
1. ______________ contributes ______________ letter? __
2. ______________ contributes ______________ letter? __
STEP 8. SIGNIFICANCE (write this LAST, as a chain)
The mechanism or clinical problem: ______________________
The decision that currently cannot be made well: ______________
Why it cannot be made well (methodological reason): ______________
The result THIS AWARD produces: ______________________
How that result changes the decision: ______________________
The step after this award, which is NOT proposed here: ______________
Burden data used? yes / no
If yes, does it discriminate this proposal from others? yes / no
If no, delete it.
[ ] No sentence claims patient benefit this award does not deliver
STEP 9. PRE-SUBMISSION
[ ] Complete draft three weeks before deadline
[ ] Structural read by someone outside the project, booked for ______
[ ] Every risk named by me, not left for the reviewer to find
[ ] Opening paragraph rewritten after significance was finalised Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica supports the elements of a cancer proposal on which the score is most often decided: reconstructing significance as a chain from mechanism to decision to deliverable, testing each aim for independence and for a scorable outcome, completing the recruitment and cost arithmetic before review, and converting an execution narrative into a costed plan with declared failure consequences. Where the proposal includes a trial or intervention, the protocol items that drive the budget are fixed before the budget is constructed.